PT1054664E - Método para modulação da ativação de macrófagos - Google Patents

Método para modulação da ativação de macrófagos Download PDF

Info

Publication number
PT1054664E
PT1054664E PT99903869T PT99903869T PT1054664E PT 1054664 E PT1054664 E PT 1054664E PT 99903869 T PT99903869 T PT 99903869T PT 99903869 T PT99903869 T PT 99903869T PT 1054664 E PT1054664 E PT 1054664E
Authority
PT
Portugal
Prior art keywords
compound
use according
pharmaceutically acceptable
disease
quot
Prior art date
Application number
PT99903869T
Other languages
English (en)
Portuguese (pt)
Inventor
Celine Morissette
Francine Gervais
Original Assignee
Bhi Ltd Partnership
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bhi Ltd Partnership filed Critical Bhi Ltd Partnership
Publication of PT1054664E publication Critical patent/PT1054664E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
PT99903869T 1998-02-11 1999-02-11 Método para modulação da ativação de macrófagos PT1054664E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7429598P 1998-02-11 1998-02-11
US24839699A 1999-02-10 1999-02-10

Publications (1)

Publication Number Publication Date
PT1054664E true PT1054664E (pt) 2012-11-02

Family

ID=26755484

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99903869T PT1054664E (pt) 1998-02-11 1999-02-11 Método para modulação da ativação de macrófagos

Country Status (12)

Country Link
EP (1) EP1054664B1 (enExample)
JP (1) JP4574845B2 (enExample)
AU (1) AU2437899A (enExample)
CA (2) CA2632106A1 (enExample)
CY (1) CY1113205T1 (enExample)
DK (1) DK1054664T3 (enExample)
ES (1) ES2392391T3 (enExample)
IL (1) IL137751A0 (enExample)
MX (2) MXPA00007815A (enExample)
NZ (2) NZ550199A (enExample)
PT (1) PT1054664E (enExample)
WO (1) WO1999040909A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
AU3726299A (en) * 1998-05-15 1999-12-06 Neurochem, Inc. Use of amyloid inhibitors for modulating neuronal cell death
US6310073B1 (en) 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
KR100822525B1 (ko) * 1999-04-28 2008-04-16 뉴로겜 인터내셔널 리미티드 아밀로이드증 치료용 조성물 및 방법
WO2001003680A2 (en) * 1999-07-09 2001-01-18 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
US6670399B2 (en) 1999-12-23 2003-12-30 Neurochem (International) Limited Compounds and methods for modulating cerebral amyloid angiopathy
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
JP2006512417A (ja) * 2002-12-24 2006-04-13 ニューロケム （インターナショナル） リミテッド β−アミロイド関連疾患の治療のための治療用製剤
CN1753662A (zh) * 2002-12-24 2006-03-29 神经化学（国际）有限公司 用于治疗β－淀粉状蛋白相关疾病的治疗制剂
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7253306B2 (en) 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
MXPA05013607A (es) * 2003-06-23 2006-04-06 Neurochem Int Ltd Candidatos de farmaco farmaceuticos mejorados y metodos para preparar los mismos.
CA2900876A1 (en) 2004-12-22 2006-08-17 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
CA2634871A1 (en) 2005-12-22 2007-11-08 Neurochem (International) Limited Treatment of renal disorders, diabetic nephopathy and dyslipidemias
PT2089417E (pt) 2006-10-12 2015-04-14 Bhi Ltd Partnership Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CA2701793C (en) 2007-10-05 2017-04-25 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
WO2010094734A2 (en) * 2009-02-19 2010-08-26 Biofocus Dpi B.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
MY174012A (en) * 2009-09-17 2020-03-03 Bespoke Bioscience Llc Role of n-2-hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2016163886A2 (en) * 2015-04-10 2016-10-13 Clues2Cure International B.V. Administration of taurine or an analog thereof for the treatment of nerve cell damage
CN109381452A (zh) * 2017-08-11 2019-02-26 江西青峰药业有限公司 乙基硫酸类化合物的应用及其制备方法
CN109381453A (zh) * 2017-08-14 2019-02-26 江西青峰药业有限公司 乙基硫酸钾在制备用于预防或治疗炎症性疾病药物中的应用
CN109394746A (zh) * 2017-08-15 2019-03-01 江西青峰药业有限公司 乙基硫酸铵在制备用于预防或治疗炎症性疾病药物中的应用
EP4514335A1 (en) 2022-04-28 2025-03-05 Alzheon, Inc. Tramiprosate for treating apoe4-related diseases
KR20250110352A (ko) 2022-12-02 2025-07-18 알제온, 인크. 트라미프로세이트를 이용하여 신경퇴행성 장애를 치료하는 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1140049A (en) * 1977-12-22 1983-01-25 Dke J.E. Helgstran Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid
US5087618A (en) * 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
EP1060750B1 (en) * 1993-03-29 2005-12-07 Queen's University At Kingston Propane-1,3-disulfonic acid and its pharmaceutically acceptable salts for treating amyloidosis
US5869469A (en) * 1997-08-18 1999-02-09 Queen's University At Kingston Phosphonocarboxylate compounds for treating amyloidosis
NZ550116A (en) * 1997-08-18 2008-03-28 Neurochem Int Ltd Phosphono-carboxylate compounds for treating amyloidosis

Also Published As

Publication number Publication date
CY1113205T1 (el) 2016-04-13
JP2002502871A (ja) 2002-01-29
IL137751A0 (en) 2001-10-31
EP1054664B1 (en) 2012-08-08
WO1999040909A1 (en) 1999-08-19
JP4574845B2 (ja) 2010-11-04
NZ568553A (en) 2010-02-26
AU2437899A (en) 1999-08-30
EP1054664A1 (en) 2000-11-29
ES2392391T3 (es) 2012-12-10
CA2320224C (en) 2008-08-12
CA2320224A1 (en) 1999-08-19
HK1032915A1 (en) 2001-08-10
CA2632106A1 (en) 1999-08-19
MX2008014823A (es) 2009-03-06
NZ550199A (en) 2008-07-31
DK1054664T3 (da) 2012-11-05
MXPA00007815A (es) 2002-04-24

Similar Documents

Publication Publication Date Title
PT1054664E (pt) Método para modulação da ativação de macrófagos
RU2215522C2 (ru) Способ эпидурального введения терапевтических соединений с поддерживаемой скоростью высвобождения, способ уменьшения угнетения дыхания
ES2283071T3 (es) Modulacion de la carga de medicamenteos en liposomas multivesiculares.
US4877619A (en) Liposomal vesicles for intraperitoneal administration of therapeutic agents
EP0243947A1 (en) Acoustic shock wave targeting of drug delivery in patients
US12329815B2 (en) Acoustic driven drug delivery systems
KR102666251B1 (ko) 약학적 조성물, 이의 제조 및 용도
EA038671B1 (ru) Способ повышения терапевтической или профилактической эффективности представляющего интерес фармацевтического соединения
JP2002515429A (ja) ニューロン細胞死を調節する方法
TW201628639A (zh) 醫藥組合物、其製備及其用途
Bagmar et al. A review on targeted drug delivery system
Takanashi et al. Intrathecal application with liposome-entrapped Fasudil for cerebral vasospasm followingsubarachnoid hemorrhage in rats
HK1032915B (en) Method for modulating macrophage activation
US12403092B2 (en) Liposomal doxorubicin formulation, method for producing a liposomal doxorubicin formulation and use of a liposomal doxorubicin formulation as a medicament
JP2002503209A (ja) 著しく改善された抗腫瘍活性によるリポソーム抗腫瘍療法
AU2006228064C1 (en) Method for modulating macrophage activation
US20230133251A1 (en) ADMINISTRATION OF mTOR INHIBITORS INTO THE CENTRAL NERVOUS SYSTEM
HK1130662A (en) Epidural administration of therapeutic compounds with sustained rate of release
WO2005007240A1 (en) Combination treatment of neurological disorders comprising phospholipids